CLRB vs CMMB

Cellectar Biosciences, Inc. vs Chemomab Therapeutics Ltd. — Valuation Comparison 2026

CLRB

Biotechnology
Cellectar Biosciences, Inc.
Quality
3.7
out of 10
Value Trap
27
LOW
Price
$3.14
Last close
Models
7/13
Active
VS

CMMB

Biotechnology
Chemomab Therapeutics Ltd.
Quality
1.9
out of 10
Value Trap
6
SAFE
Price
$2.07
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType CLRB Fair ValueCLRB Upside CMMB Fair ValueCMMB Upside
Bayesian DCF Intrinsic $1.39 -55.6% $0.55 -73.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.17 -93.7% $1.26 -39.4%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $0.07 -96.7%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CLRB vs CMMB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CLRB vs CMMB — Which Stock Is More Undervalued?

CLRB scores higher with a 3.7/10 quality rating vs CMMB's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Cellectar Biosciences, Inc. (CLRB) and Chemomab Therapeutics Ltd. (CMMB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CLRB currently trades at $3.14 with a QOC of 3.7/10, while CMMB trades at $2.07 with a QOC of 1.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).